Literature DB >> 19905926

Is exhaled nitric oxide a useful adjunctive test for assessing asthma?

Jonathan A Bernstein1, Ben Davis, María J Alvarez-Puebla, Douglas Nguyen, Linda Levin, Jose M Olaguibel.   

Abstract

RATIONALE: To determine the general utility of clinical (Asthma Control Test) and physiologic (forced expiratory volume in the first second of exhalation [FEV(1)] and fractionated exhaled nitric oxide level [FeNO]) parameters for characterizing asthma patients.
METHODS: Two cross-sectional independent studies simultaneously enrolled 100 patients in the US and 109 patients in Spain > or = 18 years of age with a physician-diagnosis of asthma and confirmed by a > or = 12% improvement in FEV(1) after bronchodilators or the presence of airway hyperresponsiveness, a central feature of asthma, as measured by methacholine challenge (PC(20) < 10 mg/mL). There was no restriction on asthma severity or treatment. Patients were excluded if they had a diagnosis of chronic obstructive pulmonary disease and/or were current cigarette smokers. Statistical analyses were performed to compare ACT, FeNO, and spirometry within and between sites.
RESULTS: Population characteristics revealed significant differences in distributions of age, percent-predicted FEV(1) (%FEV(1)), FeNO, inhaled corticosteroid usage, and atopy between the two populations. The Spain site enrolled younger patients with milder asthma, based on higher %FEV(1) values and less frequent treatment with inhaled corticosteroids. At each site, mean FeNO levels decreased as asthma control categories increased, and means were lower in the US. There was a negative correlation between ACT and FeNO that was statistically significant for Spain patients not treated with inhaled corticosteroids.
CONCLUSIONS: The results of this study support the use of FeNO as an adjunctive tool for assessing asthma primarily in mild inhaled corticosteroid (ICS)-naïve asthma patients. The lack of correlation of ACT with FeNO in this and other studies across the entire population appears to reflect the heterogeneity of asthma patients who have an admixture of asthma severity and treatment regimens making it very difficult to appreciate the nuances of sensitive tests like FeNO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19905926     DOI: 10.3109/02770900903265804

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  5 in total

1.  Irreversible airway obstruction assessed by high-resolution computed tomography (HRCT), exhaled nitric oxide (FENO), and biological markers in induced sputum in patients with asthma.

Authors:  Lanlan Zhang; Jin Gang; Cao Zhigang; Cui Yali; Shen Baozhong; Zhang Fangbiao; Chuntao Liu
Journal:  Wien Klin Wochenschr       Date:  2014-08-20       Impact factor: 1.704

2.  Significance of fractional exhaled nitric oxide combined with serum procalcitonin and C-reactive protein in evaluation of elderly asthma.

Authors:  Ji-Zhen Wu; Li-Jun Ma; Li-Min Zhao; Xiao-Yu Zhang; Xian-Liang Chen; Hong-Yan Kuang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

3.  Fractional exhaled nitric oxide is a useful adjunctive modality for monitoring bronchial asthma.

Authors:  Venkatnarayan Kavitha; Anant Mohan; Karan Madan; Vijay Hadda; G C Khilnani; Randeep Guleria
Journal:  Lung India       Date:  2017 Mar-Apr

4.  Correlation between fractional exhaled nitric oxide and Asthma Control Test score and spirometry parameters in on-treatment-asthmatics in Ho Chi Minh City.

Authors:  Vinh Nhu Nguyen; Niels H Chavannes
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

5.  Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).

Authors:  Enrico Heffler; Giovanna Elisiana Carpagnano; Elisabetta Favero; Giuseppe Guida; Mauro Maniscalco; Andrea Motta; Giovanni Paoletti; Giovanni Rolla; Eugenio Baraldi; Vincenza Pezzella; Giorgio Piacentini; Stefano Nardini
Journal:  Multidiscip Respir Med       Date:  2020-02-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.